Interview: Under the BRICS framework, China South African vaccine cooperation will benefit Africa -CEO Klein

Xinhua News Agency, Johnnesburg, June 19th. Interview: China ’s South African vaccine cooperation will benefit Africa in South Africa -CEO Klein

Xinhua News Agency reporter Jing Jing

China Kexing Company's local partner of South Africa Luo Moraz Group CEO Hilton Klein said in an exclusive interview with Xinhua News Agency that China and South Africa's vaccine cooperation can not only bring African people to the African people, Come to health dividends can also help Africa to create employment and develop economy, and eventually make "African vaccine Africa" ​​a reality.

Klein said that Luo Moraz Group and Kexing Company have cooperated with Kexing Company. Since September 2021, it has launched a phase III clinical trial against children and adolescents in South Africa from 6 months to 17 years old. The initial test plan recruited 2,000 volunteers, but the number of participants was as high as 4,500.

"The experiment showed a very positive result and did not have serious adverse reactions. Statistics showed that the inoculation of the new crown vaccine of the Kewest Crown vaccine was significantly reduced in both hospitalization and mortality." Klein said.

At present, the Luo Moraz Group is applying for clinical trials of the Kexing New Crown Vaccine Reinforcement Point to the South African Drug Administration.

"We have applied for a comprehensive approval of the Kexing vaccine in South Africa and set the vaccine age over 6 years of age. In this way, South African children will undoubtedly be better protected." Klein said that children are South Africa and Africa from Africa and Africa. In the future, how to protect children in the new crown epidemic is of great significance, the Kochi vaccine has become the choice of many parents.

Under the framework of the BRICS cooperation mechanism, China South Africa has conducted many cooperation in the new crown vaccine. In July 2021, the South African Health Products Regulatory Bureau approved the emergency use of the Koxing New Crown vaccine; in February this year, the new Chinese medicine new crown vaccine was approved for formal use in South Africa. Deepening exchanges and cooperation in joint research and development and testing, cooperative construction, authorized production, and mutual recognition of standards marks that the BRICS countries have taken another solid step to strengthen public health cooperation and vaccine research and development cooperation.

Claine believes that under the framework of the BRICS cooperation mechanism, Central and South China will certainly have more vaccine cooperation.

"Not only the new crown vaccine, but also other types of vaccines." He said that many medical groups in South Africa, including the Lu Moraz Group, are working with Chinese partners to strive to bring more burdens to the African market to bring more burdens on the African market to achieve more burdens. The vaccine, medical equipment and medicines are improved to improve the health of the local people.

"By building vaccine factories, intellectual property exchanges and multinational joint research in Africa, African people can not only improve their health, but also get more employment opportunities." He said: "At the same time, the African continent can also cooperate in BRICS With the support of the mechanism, improve your vaccine production capacity and let your own vaccine benefit your mainland. "

- END -